Biotech’s Next Frontier:

Emerging Hubs Built for Efficiency and Outsized Returns

This article examines 10 years of U.S. biotech funding to show how emerging ecosystems are creating new opportunities for founders and investors.

Inside the report:

• Established vs. emerging biotech hubs
• Capital efficiency and investor returns
• Funding, dilution, and clinical progress
• The growing opportunity in emerging U.S. markets

If you're interested in reading the full report, submit the form below and we'll email you a copy of the venture report directly.